Cohance Lifesciences Limited has received a warning letter from the US Food and Drug Administration (USFDA) concerning its Nacharam facility. The company disclosed this development through an official communication to stock exchanges under Regulation 30 of the SEBI Listing Regulations.

Regulatory Timeline and Inspection Details

The warning letter follows a USFDA inspection conducted at the company's Finished Dosage Formulations manufacturing facility (FDF Unit-I) located at Nacharam, Hyderabad, from August 4, 2025 to August 12, 2025. The company had previously communicated with stock exchanges regarding this inspection through multiple disclosures dated August 13, 2025, September 18, 2025, and October 26, 2025.

Financial Impact Assessment

The company has provided detailed financial clarity regarding the potential impact of this regulatory action. According to the official disclosure, US revenues from the affected Nacharam facility contributed less than 2% of consolidated revenues in FY2025. More significantly, the related EBITDA contribution remained below 1%, indicating minimal material impact on the company's overall financial performance.

Company Response and Commitment

Cohance Lifesciences has expressed its commitment to addressing the concerns raised by the USFDA and stated it will work with the regulatory authority to resolve these issues at the earliest. The company emphasized its dedication to maintaining the highest standards of quality and regulatory compliance across all operations.

The warning letter represents a continuation of the Official Action Indicated (OAI) classification that was previously communicated to the stock exchanges. The company remains focused on ensuring the manufacture and supply of high-quality pharmaceutical products for global markets while working toward regulatory compliance resolution.

Cohance lifesciences Limited has successfully completed its postal ballot process for a key board appointment, with shareholders overwhelmingly approving the appointment of Mr. Himanshu Agarwal as Whole-time Director. The resolution was passed on January 22, 2026, following a comprehensive remote e-voting process that demonstrated strong shareholder participation and support.

Voting Results and Shareholder Participation

The postal ballot process concluded with decisive shareholder approval, as detailed in the company's regulatory filing to BSE and NSE on January 22, 2026. The voting results showcase broad-based support across different shareholder categories.

Director Appointment Details

The approved resolution pertains to the appointment of Mr. Himanshu Agarwal, bearing Director Identification Number (DIN) 06672915, as a Whole-time Director of the Company. This appointment represents an ordinary resolution that required simple majority approval from shareholders.

E-voting Process and Timeline

The postal ballot was conducted exclusively through remote e-voting in accordance with regulatory requirements. The process was managed by KFin Technologies Limited, serving as the Company's Registrar and Transfer Agent.

Key timeline details include:

• Postal Ballot Notice Date: December 19, 2025
• Notice Distribution: December 23, 2025
• E-voting Commencement: December 24, 2025 at 9:00 AM IST
• E-voting Conclusion: January 22, 2026 at 5:00 PM IST
• Cut-off Date: December 19, 2025

Scrutinizer Report and Compliance

The voting process was overseen by DVM Gopal (ICSI Membership No. F6280), Partner of M/s. DVM & Associates LLP, who served as the appointed Scrutinizer. The scrutinizer's report confirmed that 471 members voted in favor of the resolution representing 33,10,35,115 shares (96.862%), while 51 members voted against representing 1,07,24,106 shares (3.138%). No invalid votes were recorded during the process.

The Company published the mandatory newspaper advertisement in "Business Standard" (English Daily) and "Navshakti" (Marathi Daily) on December 24, 2025, ensuring proper public notification as required under the Companies (Management and Administration) Rules, 2014.

Regulatory Compliance and Documentation

Cohance Lifesciences Limited has made the voting results and scrutinizer's report available on its official website at https://www.cohance.com/shareholder-info-2/ and on KFin Technologies Limited's e-voting platform at https://evoting.kfintech.com/ . The company's filing was signed by Kundan Kumar Jha, Company Secretary, Compliance Officer and Head-Legal, ensuring proper regulatory compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.